Institute seminar November 11th 12:00

Anne Hansen Ree and Kjersti Flatmark

A.H. Ree (left) and K. Flatmark
A.H. Ree (left) and K. Flatmark

The institute seminar on Wednesday November 11th will be held by Anne Hansen Ree and Kjersti Flatmark from Department of Tumor Biology

The title of their talk is "Functional molecular prediction and targeting of radiotherapy response"

Time and place: 12:00, Seminar Room, New Research Building, Montebello.

Institute seminars, autumn 2009

Department of Tumor Biology


Publications by Anne Hansen Ree

88 publications found

Publications 2017

  1. Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR (2017)
    Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival
    Acta Oncol, 56 (6), 813-818
    PubMed 28464745
  2. Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
    Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
    ESMO Open, 2 (2), e000158
    PubMed 28761742

Publications 2016

  1. Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K (2016)
    Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome
    Clin Oncol (R Coll Radiol), 28 (8), 532-9
    PubMed 26888115
  2. Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH (2016)
    Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
    Radiother Oncol, 119 (3), 505-11
    PubMed 26968754
  3. Grøvik E, Redalen KR, Storås TH, Negård A, Holmedal SH, Ree AH, Meltzer S, Bjørnerud A, Gjesdal KI (2016)
    Dynamic multi-echo DCE- and DSC-MRI in rectal cancer: Low primary tumor K(trans) and ΔR2* peak are significantly associated with lymph node metastasis
    J Magn Reson Imaging, 46 (1), 194-206
    PubMed 28001320
  4. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland Å, Storås TH, Hagve TA, Røsjø H, Steine K, Geisler J, Omland T (2016)
    Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
    Eur Heart J, 37 (21), 1671-80
    PubMed 26903532
  5. Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H (2016)
    Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
    Br J Cancer, 115 (8), 929-939
    PubMed 27599042
  6. Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH (2016)
    Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening
    BMC Cancer, 16, 536
    PubMed 27461255
  7. Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH (2016)
    Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy
    Cancer Res Treat, 49 (2), 374-386
    PubMed 27488871
  8. Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH (2016)
    Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer
    Oncotarget, 7 (23), 34907-17
    PubMed 27145458
  9. Ree AH (2016)
    Immune-modulating cancer therapy - back to the future
    Tidsskr Nor Laegeforen, 136 (19), 1605
    PubMed 27790877
  10. Risberg K, Redalen KR, Sønstevold L, Bjørnetrø T, Sølvernes J, Ree AH (2016)
    Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells
    BMC Cancer, 16, 531
    PubMed 27461218

Publications 2015

  1. Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH (2015)
    Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer
    BMC Cancer, 15, 543
    PubMed 26205955
  2. Hektoen HH, Ree AH, Redalen KR, Flatmark K (2015)
    Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells
    J Enzyme Inhib Med Chem, 31 (5), 779-86
    PubMed 26244271
  3. Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole KH, Dueland S, Flatmark K, Ree AH, Seierstad T (2015)
    High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer
    Radiother Oncol, 118 (2), 393-8
    PubMed 26705680
  4. Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR (2015)
    Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies
    Crit Rev Oncol Hematol, 95 (1), 114-24
    PubMed 25624177
  5. Ree AH, Redalen KR (2015)
    Personalized radiotherapy: concepts, biomarkers and trial design
    Br J Radiol, 88 (1051), 20150009
    PubMed 25989697
  6. Seierstad T, Hole KH, Grøholt KK, Dueland S, Ree AH, Flatmark K, Redalen KR (2015)
    MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer
    Br J Radiol, 88 (1051), 20150097
    PubMed 25899892

Publications 2014

  1. Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL et al. (2014)
    Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
    J Enzyme Inhib Med Chem, 30 (5), 689-721
    PubMed 25347767
  2. Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E (2014)
    Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks
    Int J Mol Sci, 15 (12), 22835-56
    PubMed 25501337
  3. Ree AH, Saelen MG, Kalanxhi E, Østensen IH, Schee K, Røe K, Abrahamsen TW, Dueland S, Flatmark K (2014)
    Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy
    PLoS One, 9 (2), e89750
    PubMed 24587009

Publications 2013

  1. Gulati G, Heck SL, Ree AH, Gravdehaug B, Røsjø H, Steine K, Bratland Å, Hoffmann P, Geisler J, Omland T (2013)
    [Cardioprotective treatment during adjuvant cancer therapy]
    Tidsskr Nor Laegeforen, 133 (17), 1832-6
    PubMed 24042297
  2. Hole KH, Larsen SG, Grøholt KK, Giercksky KE, Ree AH (2013)
    Magnetic resonance-guided histopathology for improved accuracy of tumor response evaluation of neoadjuvant treatment in organ-infiltrating rectal cancer
    Radiother Oncol, 107 (2), 178-83
    PubMed 23602370
  3. Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H (2013)
    Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer
    Int J Radiat Oncol Biol Phys, 87 (4), 753-60
    PubMed 24035332
  4. Ree AH, Hollywood D (2013)
    Design and conduct of early-phase radiotherapy trials with targeted therapeutics: lessons from the PRAVO experience
    Radiother Oncol, 108 (1), 3-16
    PubMed 23830196
  5. Røe K, Bratland Å, Vlatkovic L, Ragnum HB, Saelen MG, Olsen DR, Marignol L, Ree AH (2013)
    Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer
    PLoS One, 8 (5), e63723
    PubMed 23675504
  6. Tahiri A, Røe K, Ree AH, de Wijn R, Risberg K, Busch C, Lønning PE, Kristensen V, Geisler J (2013)
    Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma
    PLoS One, 8 (8), e72692
    PubMed 24023633

Publications 2012

  1. Heck SL, Gulati G, Ree AH, Schulz-Menger J, Gravdehaug B, Røsjø H, Steine K, Bratland A, Hoffmann P, Geisler J, Omland T (2012)
    Rationale and design of the prevention of cardiac dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial
    Cardiology, 123 (4), 240-7
    PubMed 23207160
  2. Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K (2012)
    Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer
    PLoS One, 7 (11), e50806
    PubMed 23226389
  3. Røe K, Mikalsen LT, van der Kogel AJ, Bussink J, Lyng H, Ree AH, Marignol L, Olsen DR (2012)
    Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
    Radiat Oncol, 7, 75
    PubMed 22621752
  4. Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K (2012)
    Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
    Radiat Oncol, 7, 165
    PubMed 23017053

Publications 2011

  1. Bratland A, Dueland S, Hollywood D, Flatmark K, Ree AH (2011)
    Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
    Radiat Oncol, 6, 33
    PubMed 21473790
  2. Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E (2011)
    Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma
    BMC Cancer, 11, 455
    PubMed 22014070
  3. Røe K, Kakar M, Seierstad T, Ree AH, Olsen DR (2011)
    Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study
    Radiat Oncol, 6, 65
    PubMed 21651782
  4. Saelen MG, Flatmark K, Folkvord S, de Wijn R, Rasmussen H, Fodstad Ø, Ree AH (2011)
    Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination
    Angiogenesis, 14 (4), 481-9
    PubMed 21833622

Publications 2010

  1. Bratland A, Vetrhus T, Grøholt KK, Ree AH (2010)
    Preoperative radiotherapy in rectal signet-ring cell carcinoma - magnetic resonance imaging and treatment outcome: Report of six cases
    Acta Oncol, 49 (1), 42-9
    PubMed 20100143
  2. Flatmark K, Ree AH (2010)
    Radiosensitizing drugs: lessons to be learned from the oxaliplatin story
    J Clin Oncol, 28 (29), e577-8; author reply e581-3
    PubMed 20733124
  3. Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH (2010)
    Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling
    Int J Radiat Oncol Biol Phys, 78 (2), 555-62
    PubMed 20675069
  4. Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K (2010)
    Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
    Lancet Oncol, 11 (5), 459-64
    PubMed 20378407
  5. Røe K, Aleksandersen TB, Kristian A, Nilsen LB, Seierstad T, Qu H, Ree AH, Olsen DR, Malinen E (2010)
    Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis
    Acta Oncol, 49 (7), 914-21
    PubMed 20831478
  6. Røe K, Seierstad T, Kristian A, Mikalsen LT, Mælandsmo GM, van der Kogel AJ, Ree AH, Olsen DR (2010)
    Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions
    Neoplasia, 12 (10), 818-25
    PubMed 20927320

Publications 2009

  1. Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O (2009)
    Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models
    Mol Oncol, 3 (5-6), 469-82
    PubMed 19713161
  2. Bratland A, Boender PJ, Høifødt HK, Østensen IH, Ruijtenbeek R, Wang MY, Berg JP, Lilleby W, Fodstad Ø, Ree AH (2009)
    Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling
    Clin Exp Metastasis, 26 (5), 485-96
    PubMed 19294521
  3. Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K (2009)
    Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status
    Int J Radiat Oncol Biol Phys, 74 (2), 546-52
    PubMed 19427556
  4. Seierstad T, Hole KH, Saelen E, Ree AH, Flatmark K, Malinen E (2009)
    MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy
    Radiother Oncol, 93 (2), 279-84
    PubMed 19800704

Publications 2008

  1. Ree AH (2008)
    Highly proliferative neuroendocrine carcinoma - influence of radiotherapy fractionation on tumor response
    Radiat Oncol, 3, 13
    PubMed 18489745
  2. Ree AH, Bratland A, Dueland S (2008)
    [Molecular targeted therapy in colorectal cancer]
    Tidsskr Nor Laegeforen, 128 (2), 190-3
    PubMed 18202731
  3. Ree AH, Folkvord S, Flatmark K (2008)
    HDAC2 deficiency and histone acetylation
    Nat Genet, 40 (7), 812-3; author reply 813
    PubMed 18583969
  4. Seierstad T, Røe K, Sitter B, Halgunset J, Flatmark K, Ree AH, Olsen DR, Gribbestad IS, Bathen TF (2008)
    Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy
    Mol Cancer, 7, 33
    PubMed 18439252

Publications 2007

  1. Folkvord S, Flatmark K, Seierstad T, Røe K, Rasmussen H, Ree AH (2007)
    Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?
    Radiother Oncol, 86 (3), 428-34
    PubMed 18006097
  2. Paulsen T, Ree AH, Kaern J, Kjaerheim K, Bassarova A, Berner A, Haldorsen T, Tropé C, Nesland JM (2007)
    Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation
    Eur J Gynaecol Oncol, 28 (5), 356-63
    PubMed 17966213

Publications 2006

  1. Dahm AE, Iversen N, Birkenes B, Ree AH, Sandset PM (2006)
    Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1
    BMC Cardiovasc Disord, 6, 40
    PubMed 17029634
  2. Flatmark K, Nome RV, Folkvord S, Bratland A, Rasmussen H, Ellefsen MS, Fodstad Ø, Ree AH (2006)
    Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition
    Radiat Oncol, 1, 25
    PubMed 16887021
  3. Ree AH (2006)
    A complex case of rectal neuroendocrine carcinoma with terminal delirium
    Nat Clin Pract Gastroenterol Hepatol, 3 (7), 408-13; quiz 414
    PubMed 16819503
  4. Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y (2006)
    DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting
    Anticancer Res, 26 (3A), 1909-16
    PubMed 16827124

Publications 2005

  1. Lyng H, Landsverk KS, Kristiansen E, DeAngelis PM, Ree AH, Myklebost O, Hovig E, Stokke T (2005)
    Response of malignant B lymphocytes to ionizing radiation: gene expression and genotype
    Int J Cancer, 115 (6), 935-42
    PubMed 15723354
  2. Nome RV, Bratland A, Harman G, Fodstad O, Andersson Y, Ree AH (2005)
    Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death
    Mol Cancer Ther, 4 (8), 1231-8
    PubMed 16093439
  3. Porojnicu AC, Robsahm TE, Ree AH, Moan J (2005)
    Season of diagnosis is a prognostic factor in Hodgkin's lymphoma: a possible role of sun-induced vitamin D
    Br J Cancer, 93 (5), 571-4
    PubMed 16136030

Publications 2004

  1. DeMasters GA, Gupta MS, Jones KR, Cabot M, Wang H, Gennings C, Park M, Bratland A, Ree AH, Gewirtz DA (2004)
    Potentiation of cell killing by fractionated radiation and suppression of proliferative recovery in MCF-7 breast tumor cells by the Vitamin D3 analog EB 1089
    J Steroid Biochem Mol Biol, 92 (5), 365-74
    PubMed 15698541
  2. Johansson CC, Yndestad A, Enserink JM, Ree AH, Aukrust P, Taskén K (2004)
    The epidermal growth factor-like growth factor amphiregulin is strongly induced by the adenosine 3',5'-monophosphate pathway in various cell types
    Endocrinology, 145 (11), 5177-84
    PubMed 15284208
  3. Ree AH (2004)
    [Cell cycle-targeted therapy]
    Tidsskr Nor Laegeforen, 124 (19), 2479-82
    PubMed 15477884
  4. Ree AH, Bratland A, Nome RV, Stokke T, Fodstad O, Andersson Y (2004)
    Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization?
    Radiother Oncol, 72 (3), 305-10
    PubMed 15450729
  5. Ree AH, Bratland A, Solberg Landsverk K, Fodstad O (2004)
    Ionizing radiation inhibits the PLK cell cycle gene in a G2 checkpoint-dependent manner
    Anticancer Res, 24 (2B), 555-62
    PubMed 15160994

Publications 2003

  1. Bratland A, Ragnhildstveit E, Bjørnland K, Andersen K, Maelandsmo GM, Fodstad O, Saatcioglu F, Ree AH (2003)
    The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells
    Clin Exp Metastasis, 20 (6), 541-7
    PubMed 14598888
  2. Ree AH, Bratland A, Nome RV, Stokke T, Fodstad Ø (2003)
    Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1
    Oncogene, 22 (55), 8952-5
    PubMed 14654792

Publications 2002

  1. Ree AH, Bratland A, Kroes RA, Aasheim HC, Flørenes VA, Moskal JR, Fodstad O, Bruland OS, Maelandsmo GM (2002)
    Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases
    Anticancer Res, 22 (4), 1949-57
    PubMed 12174869
  2. Ree AH, Engebraaten O, Hovig E, Fodstad Ø (2002)
    Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: gene expression profiles in bone marrow target cells
    Int J Cancer, 97 (1), 28-33
    PubMed 11774240

Publications 2001

  1. Bjørnland K, Bratland A, Rugnes E, Pettersen S, Johansen HT, Aasen AO, Fodstad Ø, Ree AH, Maelandsmo GM (2001)
    Expression of matrix metalloproteinases and the metastasis-associated gene S100A4 in human neuroblastoma and primitive neuroectodermal tumor cells
    J Pediatr Surg, 36 (7), 1040-4
    PubMed 11431772

Publications 2000

  1. Bratland A, Risberg K, Maelandsmo GM, Gützkow KB, Olsen OE, Moghaddam A, Wang MY, Hansen CM, Blomhoff HK, Berg JP, Fodstad O, Ree AH (2000)
    Expression of a novel factor, com1, is regulated by 1,25-dihydroxyvitamin D3 in breast cancer cells
    Cancer Res, 60 (19), 5578-83
    PubMed 11034106
  2. Grønning LM, Wang JE, Ree AH, Haugen TB, Taskén K, Taskén KA (2000)
    Regulation of tissue inhibitor of metalloproteinases-1 in rat Sertoli cells: induction by germ cell residual bodies, interleukin-1alpha, and second messengers
    Biol Reprod, 62 (4), 1040-6
    PubMed 10727275
  3. Ree AH, Pacheco MM, Tvermyr M, Fodstad O, Brentani MM (2000)
    Expression of a novel factor, com1, in early tumor progression of breast cancer
    Clin Cancer Res, 6 (5), 1778-83
    PubMed 10815897

Publications 1999

  1. Ree AH, Hansson V, Walaas SI, Eskild W, Taskén KA (1999)
    Calcium/phospholipid-dependent protein kinases in rat Sertoli cells: regulation of androgen receptor messenger ribonucleic acid
    Biol Reprod, 60 (5), 1257-62
    PubMed 10208993
  2. Ree AH, Tvermyr M, Engebraaten O, Rooman M, Røsok O, Hovig E, Meza-Zepeda LA, Bruland OS, Fodstad O (1999)
    Expression of a novel factor in human breast cancer cells with metastatic potential
    Cancer Res, 59 (18), 4675-80
    PubMed 10493524
  3. Røsok O, Pedeutour F, Ree AH, Aasheim HC (1999)
    Identification and characterization of TESK2, a novel member of the LIMK/TESK family of protein kinases, predominantly expressed in testis
    Genomics, 61 (1), 44-54
    PubMed 10512679
  4. Ståhl S, Odeberg J, Larsson M, Røsok O, Ree AH, Lundeberg J (1999)
    Solid-phase differential display and bacterial expression systems in selection and functional analysis of cDNAs
    Methods Enzymol, 303, 495-511
    PubMed 10349662

Publications 1998

  1. Bjørnland K, Lehne G, Johansen HT, Fodstad O, Rugstad HE, Aasen AO, Ree AH (1998)
    Human hepatoma cells rich in P-glycoprotein display enhanced in vitro invasive properties compared to P-glycoprotein-poor hepatoma cells
    Oncol Res, 10 (5), 255-62
    PubMed 9802060
  2. Ree AH, Bjørnland K, Brünner N, Johansen HT, Pedersen KB, Aasen AO, Fodstad O (1998)
    Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells
    Clin Exp Metastasis, 16 (3), 205-15
    PubMed 9568638

Publications 1997

  1. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O (1997)
    High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases
    Clin Cancer Res, 3 (9), 1623-8
    PubMed 9815852

Publications 1996

  1. Ree AH, Maelandsmo GM, Fodstad O (1996)
    Regulation of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in MCF-7 cells: comparison with regulatory mechanisms of pS2 expression
    Clin Exp Metastasis, 14 (4), 381-8
    PubMed 8878412

Publications 1994

  1. Berg JP, Ree AH, Sandvik JA, Taskén K, Landmark BF, Torjesen PA, Haug E (1994)
    1,25-dihydroxyvitamin D3 alters the effect of cAMP in thyroid cells by increasing the regulatory subunit type II beta of the cAMP-dependent protein kinase
    J Biol Chem, 269 (51), 32233-8
    PubMed 7798223
  2. Berg JP, Sandvik JA, Ree AH, Sørnes G, Bjøro T, Torjesen PA, Gordeladze JO, Haug E (1994)
    1,25-Dihydroxyvitamin D3 attenuates adenylyl cyclase activity in rat thyroid cells: reduction of thyrotropin receptor number and increase in guanine nucleotide-binding protein Gi-2 alpha
    Endocrinology, 135 (2), 595-602
    PubMed 8033808
  3. Ree AH, Taskén K, Hansson V (1994)
    Regulation of glucocorticoid receptor (GR) mRNA and protein levels by phorbol ester in MCF-7 cells. Mechanism of GR mRNA induction and decay
    J Steroid Biochem Mol Biol, 48 (1), 23-9
    PubMed 8136303

Publications 1992

  1. Kise NJ, Bergsmark JK, Endreseth BH, Reinertsen KV, Ugelstad TP, Ree AH (1992)
    [Living and dying alone. An epidemiological study of deaths outside institutions in Oslo in 1989]
    Tidsskr Nor Laegeforen, 112 (5), 616-9
    PubMed 1557724

Publications 1991

  1. Eskild W, Ree AH, Levy FO, Jahnsen T, Hansson V (1991)
    Cellular localization of mRNAs for retinoic acid receptor-alpha, cellular retinol-binding protein, and cellular retinoic acid-binding protein in rat testis: evidence for germ cell-specific mRNAs
    Biol Reprod, 44 (1), 53-61
    PubMed 1849753
  2. Ree AH, Landmark BF, Walaas SI, Lahooti H, Eikvar L, Eskild W, Hansson V (1991)
    Down-regulation of messenger ribonucleic acid and protein levels for estrogen receptors by phorbol ester and calcium in MCF-7 cells
    Endocrinology, 129 (1), 339-44
    PubMed 2055193

Publications 1990

  1. Ree AH, Frøysa A, Eskild W, Jahnsen T, Hansson V (1990)
    Biphasic regulation of the messenger ribonucleic acid coding for the estrogen receptor by cyclic adenosine 3':5'-monophosphate in tumor Leydig cells
    Cancer Res, 50 (5), 1528-31
    PubMed 2154326

Publications 1989

  1. Levy FO, Ree AH, Eikvar L, Govindan MV, Jahnsen T, Hansson V (1989)
    Glucocorticoid receptors and glucocorticoid effects in rat Sertoli cells
    Endocrinology, 124 (1), 430-6
    PubMed 2909375
  2. Ree AH, Landmark BF, Eskild W, Levy FO, Lahooti H, Jahnsen T, Aakvaag A, Hansson V (1989)
    Autologous down-regulation of messenger ribonucleic acid and protein levels for estrogen receptors in MCF-7 cells: an inverse correlation to progesterone receptor levels
    Endocrinology, 124 (5), 2577-83
    PubMed 2651098

Publications by Kjersti Flatmark

84 publications found

Publications 2017

  1. Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR (2017)
    Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival
    Acta Oncol, 56 (6), 813-818
    PubMed 28464745
  2. Flem-Karlsen K, Tekle C, Andersson Y, Flatmark K, Fodstad Ø, Nunes-Xavier CE (2017)
    Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells
    Pigment Cell Melanoma Res (in press)
    PubMed 28513992
  3. Fretland ÅA, Dagenborg VJ, Bjørnelv GMW, Kazaryan AM, Kristiansen R, Fagerland MW, Hausken J, Tønnessen TI, Abildgaard A, Barkhatov L, Yaqub S, Røsok BI, Bjørnbeth BA, Andersen MH, Flatmark K, Aas E, Edwin B, Oslo-CoMet study group (2017)
    Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial
    Ann Surg (in press)
    PubMed 28657937
  4. Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Olsen KH, Giercksky KE, Julsrud L, Fodstad Ø, Dueland S, Flatmark K (2017)
    Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial
    Ann Surg Oncol, 24 (7), 1916-1922
    PubMed 28224367
  5. Graudenzi A, Cava C, Bertoli G, Fromm B, Flatmark K, Mauri G, Castiglioni I (2017)
    Pathway-based classification of breast cancer subtypes
    Front. Biosci., 22, 1697-1712
  6. Graudenzi A, Cava C, Bertoli G, Fromm B, Flatmark K, Mauri G, Castiglioni I (2017)
    Pathway-based classification of breast cancer subtypes
    Front Biosci (Landmark Ed), 22, 1697-1712
    PubMed 28410140
  7. Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
    Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
    ESMO Open, 2 (2), e000158
    PubMed 28761742

Publications 2016

  1. Boye K, Jacob H, Frikstad KA, Nesland JM, Maelandsmo GM, Dahl O, Nesbakken A, Flatmark K (2016)
    Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy
    Cancer Med, 5 (8), 1840-9
    PubMed 27273130
  2. Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K (2016)
    Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome
    Clin Oncol (R Coll Radiol), 28 (8), 532-9
    PubMed 26888115
  3. Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K (2016)
    Expression and clinical significance of Wee1 in colorectal cancer
    Tumour Biol, 37 (9), 12133-12140
    PubMed 27220319
  4. Flatmark K, Høye E, Fromm B (2016)
    microRNAs as cancer biomarkers
    Scand J Clin Lab Invest Suppl, 245, S80-3
    PubMed 27542003
  5. Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH (2016)
    Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
    Radiother Oncol, 119 (3), 505-11
    PubMed 26968754
  6. Fleten KG, Bakke KM, Mælandsmo GM, Abildgaard A, Redalen KR, Flatmark K (2016)
    Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases
    Clin Exp Metastasis, 34 (1), 51-62
    PubMed 27812769
  7. Frøysnes IS, Larsen SG, Spasojevic M, Dueland S, Flatmark K (2016)
    Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort
    J Surg Oncol, 114 (2), 222-7
    PubMed 27173150
  8. Goscinski MA, Hole KH, Tønne E, Ryder T, Grøholt KK, Flatmark K (2016)
    Fibromatosis in vertical rectus abdominis myocutaneous flap imitating tumor recurrence after surgery for locally advanced rectal cancer: case report
    World J Surg Oncol, 14, 63
    PubMed 26940557
  9. Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H (2016)
    Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
    Br J Cancer, 115 (8), 929-939
    PubMed 27599042
  10. Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH (2016)
    Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening
    BMC Cancer, 16, 536
    PubMed 27461255
  11. Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH (2016)
    Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy
    Cancer Res Treat, 49 (2), 374-386
    PubMed 27488871
  12. Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH (2016)
    Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer
    Oncotarget, 7 (23), 34907-17
    PubMed 27145458
  13. Thorgersen EB, Goscinski MA, Spasojevic M, Solbakken AM, Mariathasan AB, Boye K, Larsen SG, Flatmark K (2016)
    Deep Pelvic Surgical Site Infection After Radiotherapy and Surgery for Locally Advanced Rectal Cancer
    Ann Surg Oncol, 24 (3), 721-728
    PubMed 27766561

Publications 2015

  1. Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM (2015)
    Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes
    Clin Exp Metastasis, 32 (8), 755-67
    PubMed 26349943
  2. Fretland ÅA, Kazaryan AM, Bjørnbeth BA, Flatmark K, Andersen MH, Tønnessen TI, Bjørnelv GM, Fagerland MW, Kristiansen R, Øyri K, Edwin B (2015)
    Open versus laparoscopic liver resection for colorectal liver metastases (the Oslo-CoMet Study): study protocol for a randomized controlled trial
    Trials, 16, 73
    PubMed 25872027
  3. Fromm B, Billipp T, Peck LE, Johansen M, Tarver JE, King BL, Newcomb JM, Sempere LF, Flatmark K, Hovig E, Peterson KJ (2015)
    A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome
    Annu Rev Genet, 49, 213-42
    PubMed 26473382
  4. Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH (2015)
    Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer
    BMC Cancer, 15, 543
    PubMed 26205955
  5. Hektoen HH, Ree AH, Redalen KR, Flatmark K (2015)
    Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells
    J Enzyme Inhib Med Chem, 31 (5), 779-86
    PubMed 26244271
  6. Lambrecht JR, Larsen SG, Reiertsen O, Vaktskjold A, Julsrud L, Flatmark K (2015)
    Prophylactic mesh at end-colostomy construction reduces parastomal hernia rate: a randomized trial
    Colorectal Dis, 17 (10), O191-7
    PubMed 26179984
  7. Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole KH, Dueland S, Flatmark K, Ree AH, Seierstad T (2015)
    High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer
    Radiother Oncol, 118 (2), 393-8
    PubMed 26705680
  8. Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR (2015)
    Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies
    Crit Rev Oncol Hematol, 95 (1), 114-24
    PubMed 25624177
  9. Seierstad T, Hole KH, Grøholt KK, Dueland S, Ree AH, Flatmark K, Redalen KR (2015)
    MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer
    Br J Radiol, 88 (1051), 20150097
    PubMed 25899892

Publications 2014

  1. Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K (2014)
    High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting
    Eur J Cancer, 51 (1), 9-17
    PubMed 25466510
  2. Ingebrigtsen VA, Boye K, Nesland JM, Nesbakken A, Flatmark K, Fodstad Ø (2014)
    B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome
    BMC Cancer, 14, 602
    PubMed 25139714
  3. Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL et al. (2014)
    Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
    J Enzyme Inhib Med Chem, 30 (5), 689-721
    PubMed 25347767
  4. Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E (2014)
    Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks
    Int J Mol Sci, 15 (12), 22835-56
    PubMed 25501337
  5. Ree AH, Saelen MG, Kalanxhi E, Østensen IH, Schee K, Røe K, Abrahamsen TW, Dueland S, Flatmark K (2014)
    Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy
    PLoS One, 9 (2), e89750
    PubMed 24587009
  6. Wiiger MT, Bideli H, Fodstad O, Flatmark K, Andersson Y (2014)
    The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells
    J Ovarian Res, 7, 23
    PubMed 24528603

Publications 2013

  1. Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y (2013)
    Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
    Int J Cancer, 133 (6), 1497-506
    PubMed 23494569
  2. Friedman R, Boye K, Flatmark K (2013)
    Molecular modelling and simulations in cancer research
    Biochim Biophys Acta, 1836 (1), 1-14
    PubMed 23416097
  3. Haugen MH, Johansen HT, Pettersen SJ, Solberg R, Brix K, Flatmark K, Maelandsmo GM (2013)
    Nuclear legumain activity in colorectal cancer
    PLoS One, 8 (1), e52980
    PubMed 23326369
  4. Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H (2013)
    Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer
    Int J Radiat Oncol Biol Phys, 87 (4), 753-60
    PubMed 24035332
  5. Rud AK, Borgen E, Mælandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland Å, Jørgensen L, Brustugun OT, Fodstad Ø, Boye K (2013)
    Clinical significance of disseminated tumour cells in non-small cell lung cancer
    Br J Cancer, 109 (5), 1264-70
    PubMed 23942067
  6. Schee K, Lorenz S, Worren MM, Günther CC, Holden M, Hovig E, Fodstad O, Meza-Zepeda LA, Flatmark K (2013)
    Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer
    PLoS One, 8 (6), e66165
    PubMed 23824282
  7. Sørensen O, Andersen AM, Kristian A, Giercksky KE, Flatmark K (2013)
    Impact of hyperthermia on pharmacokinetics of intraperitoneal mitomycin C in rats investigated by microdialysis
    J Surg Oncol, 109 (6), 521-6
    PubMed 24347444
  8. Zhai H, Fesler A, Schee K, Fodstad O, Flatmark K, Ju J (2013)
    Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer
    Clin Colorectal Cancer, 12 (4), 261-6
    PubMed 24012455

Publications 2012

  1. Boye K, Nesland JM, Sandstad B, Haugland Haugen M, Mælandsmo GM, Flatmark K (2012)
    EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer
    Br J Cancer, 107 (4), 667-74
    PubMed 22782346
  2. Brusegard K, Stavnes HT, Nymoen DA, Flatmark K, Trope CG, Davidson B (2012)
    Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
    Virchows Arch, 460 (2), 193-202
    PubMed 22249560
  3. Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O (2012)
    B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer
    Int J Cancer, 131 (11), 2528-36
    PubMed 22473715
  4. Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K (2012)
    Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer
    PLoS One, 7 (11), e50806
    PubMed 23226389
  5. Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K (2012)
    Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
    Radiat Oncol, 7, 165
    PubMed 23017053
  6. Schee K, Boye K, Abrahamsen TW, Fodstad Ø, Flatmark K (2012)
    Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer
    BMC Cancer, 12, 505
    PubMed 23121918
  7. Schee K, Flatmark K, Holm R, Boye K, Paus E (2012)
    Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients (vol 33, pg 73, 2012)
    Tumor Biol., 33 (4), 1263-1264
  8. Sørensen O, Flatmark K, Reed W, Wiig JN, Dueland S, Giercksky KE, Larsen SG (2012)
    Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei
    Eur J Surg Oncol, 38 (10), 969-76
    PubMed 22763244

Publications 2011

  1. Bratland A, Dueland S, Hollywood D, Flatmark K, Ree AH (2011)
    Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
    Radiat Oncol, 6, 33
    PubMed 21473790
  2. Flatmark K, Borgen E, Nesland JM, Rasmussen H, Johannessen HO, Bukholm I, Rosales R, Hårklau L, Jacobsen HJ, Sandstad B, Boye K, Fodstad Ø (2011)
    Disseminated tumour cells as a prognostic biomarker in colorectal cancer
    Br J Cancer, 104 (9), 1434-9
    PubMed 21448171
  3. Saelen MG, Flatmark K, Folkvord S, de Wijn R, Rasmussen H, Fodstad Ø, Ree AH (2011)
    Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination
    Angiogenesis, 14 (4), 481-9
    PubMed 21833622
  4. Schee K, Flatmark K, Holm R, Boye K, Paus E (2011)
    Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients
    Tumour Biol, 33 (1), 73-83
    PubMed 22006279
  5. Wiig JN, Larsen SG, Dueland S, Flatmark K, Giercksky KE (2011)
    Salvage surgery for locally recurrent rectal cancer: total mesorectal excision during the primary operation does not influence the outcome
    Colorectal Dis, 13 (5), 506-11
    PubMed 20236148

Publications 2010

  1. Berge G, Costea DE, Berg M, Rasmussen H, Grotterød I, Lothe RA, Mælandsmo GM, Flatmark K (2010)
    Coexpression and nuclear colocalization of metastasis-promoting protein S100A4 and p53 without mutual regulation in colorectal carcinoma
    Amino Acids, 41 (4), 875-84
    PubMed 20191297
  2. Boye K, Nesland JM, Sandstad B, Mælandsmo GM, Flatmark K (2010)
    Nuclear S100A4 is a novel prognostic marker in colorectal cancer
    Eur J Cancer, 46 (16), 2919-25
    PubMed 20719498
  3. Flatmark K, Davidson B, Kristian A, Stavnes HT, Førsund M, Reed W (2010)
    Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models
    Hum Pathol, 41 (8), 1109-19
    PubMed 20338618
  4. Flatmark K, Ree AH (2010)
    Radiosensitizing drugs: lessons to be learned from the oxaliplatin story
    J Clin Oncol, 28 (29), e577-8; author reply e581-3
    PubMed 20733124
  5. Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH (2010)
    Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling
    Int J Radiat Oncol Biol Phys, 78 (2), 555-62
    PubMed 20675069
  6. Paus E, Haugen MH, Olsen KH, Flatmark K, Maelandsmo GM, Nilsson O, Röijer E, Lundin M, Fermér C, Samsonova M, Lebedin Y, Stigbrand T (2010)
    TD-11 workshop report: characterization of monoclonal antibodies to S100 proteins
    Tumour Biol, 32 (1), 1-12
    PubMed 20652782
  7. Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K (2010)
    Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
    Lancet Oncol, 11 (5), 459-64
    PubMed 20378407
  8. Schee K, Fodstad Ø, Flatmark K (2010)
    MicroRNAs as biomarkers in colorectal cancer
    Am J Pathol, 177 (4), 1592-9
    PubMed 20829435
  9. Sørensen O, Andersen A, Olsen H, Alexandr K, Ekstrøm PO, Giercksky KE, Flatmark K (2010)
    Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C - an experimental study
    BMC Cancer, 10, 469
    PubMed 20809961

Publications 2009

  1. Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K (2009)
    Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status
    Int J Radiat Oncol Biol Phys, 74 (2), 546-52
    PubMed 19427556
  2. Maelandsmo GM, Flørenes VA, Nguyen MT, Flatmark K, Davidson B (2009)
    Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites
    Tumour Biol, 30 (1), 15-25
    PubMed 19194111
  3. Seierstad T, Hole KH, Saelen E, Ree AH, Flatmark K, Malinen E (2009)
    MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy
    Radiother Oncol, 93 (2), 279-84
    PubMed 19800704

Publications 2008

  1. Brunsvig PF, Flatmark K, Aamdal S, Høifødt H, Le H, Jakobsen E, Sandstad B, Fodstad O (2008)
    Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients
    Lung Cancer, 61 (2), 170-6
    PubMed 18261824
  2. Haugen MH, Flatmark K, Mikalsen SO, Malandsmo GM (2008)
    The metastasis-associated protein S100A4 exists in several charged variants suggesting the presence of posttranslational modifications
    BMC Cancer, 8, 172
    PubMed 18554396
  3. Ree AH, Folkvord S, Flatmark K (2008)
    HDAC2 deficiency and histone acetylation
    Nat Genet, 40 (7), 812-3; author reply 813
    PubMed 18583969
  4. Seierstad T, Røe K, Sitter B, Halgunset J, Flatmark K, Ree AH, Olsen DR, Gribbestad IS, Bathen TF (2008)
    Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy
    Mol Cancer, 7, 33
    PubMed 18439252

Publications 2007

  1. Flatmark K, Reed W, Halvorsen T, Sørensen O, Wiig JN, Larsen SG, Fodstad Ø, Giercksky KE (2007)
    Pseudomyxoma peritonei--two novel orthotopic mouse models portray the PMCA-I histopathologic subtype
    BMC Cancer, 7, 116
    PubMed 17603904
  2. Folkvord S, Flatmark K, Seierstad T, Røe K, Rasmussen H, Ree AH (2007)
    Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?
    Radiother Oncol, 86 (3), 428-34
    PubMed 18006097
  3. Seierstad T, Folkvord S, Røe K, Flatmark K, Skretting A, Olsen DR (2007)
    Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice
    Neoplasia, 9 (5), 392-400
    PubMed 17534444

Publications 2006

  1. Flatmark K, Nome RV, Folkvord S, Bratland A, Rasmussen H, Ellefsen MS, Fodstad Ø, Ree AH (2006)
    Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition
    Radiat Oncol, 1, 25
    PubMed 16887021
  2. Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y (2006)
    DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting
    Anticancer Res, 26 (3A), 1909-16
    PubMed 16827124

Publications 2005

  1. Bjørnland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O, Maelandsmo GM (2005)
    Matrix metalloproteinases participate in osteosarcoma invasion
    J Surg Res, 127 (2), 151-6
    PubMed 16083752

Publications 2004

  1. Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, Fodstad Ø (2004)
    Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice
    Eur J Cancer, 40 (10), 1593-8
    PubMed 15196545
  2. Flatmark K, Maelandsmo GM, Mikalsen SO, Nustad K, Varaas T, Rasmussen H, Meling GI, Fodstad Ø, Paus E (2004)
    Immunofluorometric assay for the metastasis-related protein S100A4: release of S100A4 from normal blood cells prohibits the use of S100A4 as a tumor marker in plasma and serum
    Tumour Biol, 25 (1-2), 31-40
    PubMed 15192310

Publications 2003

  1. Bjørnland K, Flatmark K, Mala T, Mathisen O, Bakka A, Aasen AO, Bergan A, Søreide O, Fodstad O (2003)
    Detection of disseminated tumour cells in bone marrow of patients with isolated liver metastases from colorectal cancer
    J Surg Oncol, 82 (4), 224-7
    PubMed 12672004
  2. Flatmark K, Pedersen KB, Nesland JM, Rasmussen H, Aamodt G, Mikalsen SO, Bjørnland K, Fodstad Ø, Maelandsmo GM (2003)
    Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer
    J Pathol, 200 (5), 589-95
    PubMed 12898594

Publications 2002

  1. Flatmark K, Bjørnland K, Johannessen HO, Hegstad E, Rosales R, Hårklau L, Solhaug JH, Faye RS, Søreide O, Fodstad Ø, Study Group for Micrometastases in BM in Colorectal Cancer (2002)
    Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients
    Clin Cancer Res, 8 (2), 444-9
    PubMed 11839662

Publications 2000

  1. Flatmark K, Nilsen BH (2000)
    [Postoperative wound infections in elective colorectal surgery]
    Tidsskr Nor Laegeforen, 120 (23), 2761-3
    PubMed 11107920